<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy R Sterling, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Bernardo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Roy M Gulick, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 01, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initiation of treatment of drug-susceptible pulmonary tuberculosis (TB) in adults with human immunodeficiency virus (HIV) must address potential drug interactions, adverse reactions including the immune reconstitution inflammatory syndrome, and optimal timing for initiation of antiretroviral therapy (ART) in ART-naïve patients [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p>
         Issues related to initiation of therapy for treatment of patients with HIV and TB infection are reviewed here. Issues related to follow-up after initiation of therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         .)
        </p>
        <p>
         General principles related to antituberculous therapy for treatment of drug-susceptible TB in HIV-uninfected adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p>
         The clinical features and diagnosis of TB disease in patients with HIV are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p>
         Beyond issues related to ART discussed here, general principles related to ART are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">
          "Overview of antiretroviral agents used to treat HIV"
         </a>
         .)
        </p>
        <p>
         Issues related to drug-resistant TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of TB in patients with HIV infection should include attention to the following principles:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection control – Issues related to TB transmission and control are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/8000.html" rel="external">
          "Tuberculosis transmission and control in health care settings"
         </a>
         ). The principles are the same for patients with HIV infection as they are for patients without HIV infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of an appropriate regimen for pulmonary TB – The antituberculous regimen must be designed with close attention to potential drug interactions with antiretroviral agents. The initial regimen usually is empiric and must be tailored to drug susceptibility results when available. (See
         <a class="local">
          'Regimen selection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical case management with directly observed therapy (DOT) – All patients with TB should be treated with clinical case management and DOT; it is the most effective way to maximize adherence and is recommended by the World Health Organization (WHO) [
         <a href="#rid1">
          1,6
         </a>
         ]. DOT programs are very effective in decreasing rates of primary and acquired drug resistance [
         <a href="#rid7">
          7,8
         </a>
         ]. In countries where TB and HIV are endemic, DOT has been associated with lower TB relapse rates and a higher percentage of patients who complete the full duration of TB therapy [
         <a href="#rid9">
          9,10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of appropriate antiretroviral therapy (ART) for HIV – Initiation or revision of ART must be made with close attention to the timing of initiation as well as potential drug interactions with TB medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (for patients with baseline CD4 cell count &lt;100 cells/microL and starting ART within 30 days of starting antituberculous treatment), to reduce the likelihood of immune reconstitution inflammatory syndrome (IRIS) – IRIS can present as a paradoxical worsening of a pre-existing infectious process (eg, TB) following immune recovery associated with administration of ART. The risk of IRIS appears to depend on the baseline CD4 cell count (baseline CD4 cell count &lt;50 cells/microL confers greatest risk) and the timing of ART initiation relative to TB medications. (See
         <a class="local">
          'Timing'
         </a>
         below and
         <a class="local">
          'Preventing IRIS'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy", section on 'Immune reconstitution inflammatory syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Close monitoring for treatment response – The approach to follow-up after initiation of therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3403778028">
         <span class="h1">
          ROLE OF EMPIRIC TB THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Establishing a definitive laboratory diagnosis of TB may not be possible in some circumstances. A presumptive clinical diagnosis may be based on epidemiologic exposure together with physical findings, radiographic findings, positive
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         or interferon-gamma release assay, analysis of sputum or bronchoscopy specimens, and/or histopathology. In the setting of high clinical suspicion for TB, initiation of empiric therapy based on these findings is appropriate. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'General diagnostic approach'
         </a>
         .)
        </p>
        <p>
         However, in the absence of specific clinical suspicion for TB, there is no role for routine administration of empiric antituberculous therapy among patients with HIV. Such an approach has been proposed in regions with high burdens of TB and HIV, where many patients with HIV infection are severely immunocompromised at presentation; diagnosing TB is often difficult in such cases, given the often atypical clinical manifestations and limited sensitivity of diagnostic tools [
         <a href="#rid11">
          11,12
         </a>
         ]. However, this approach does not improve survival and confers increased risk of adverse drug reactions [
         <a href="#rid13">
          13-15
         </a>
         ]. In one randomized trial including more than 1000 adults with HIV infection and CD4 cell count &lt;100 cells/microL in four countries with high burden of HIV and TB, administration of empiric antituberculous therapy was not superior to test-guided treatment in reducing mortality at 24 weeks (rate of death from any cause or invasive bacterial disease 19.4 versus 20.3 events per 100 patient-years; adjusted hazard ratio 0.95, 95% CI 0.63-1.44) [
         <a href="#rid13">
          13
         </a>
         ]. Patients who received empiric treatment had a lower rate of TB (3.0 versus 17.9 percent; adjusted hazard ratio 0.15, 95% CI 0.09-0.26), but higher rate of serious adverse events (17.4 versus 7.2 percent; adjusted hazard ratio 2.57, 95% CI 1.75-3.78).
        </p>
        <p class="headingAnchor" id="H319082495">
         <span class="h1">
          TB DIAGNOSED PRIOR TO HIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with an established diagnosis of TB disease warrant prompt initiation of antituberculous therapy as well as HIV testing. Patients with TB who are HIV infected warrant initiation of antiretroviral therapy (ART) regardless of CD4 count [
         <a href="#rid1">
          1,4,6
         </a>
         ]; the approach is discussed in the following sections.
        </p>
        <p class="headingAnchor" id="H3100743462">
         <span class="h2">
          Antituberculous therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2605053190">
         <span class="h3">
          Initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with pulmonary TB should begin antituberculous therapy promptly. Pending drug susceptibility testing results, a four-drug regimen should be initiated (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin [eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ],
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ) with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         and daily therapy using directly observed therapy (DOT)  (
         <a class="graphic graphic_table graphicRef58653" href="/z/d/graphic/58653.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H563844985">
         <span class="h3">
          Regimen selection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         − For treatment of drug-susceptible pulmonary TB, options include the traditional regimen (≥6 months) or a shortened rifapentine-moxifloxacin (four-month) regimen. The traditional regimen remains standard of care; the shortened regimen may be used in a subset of patients who fulfill specific criteria as described below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rifamycin nitrosamine impurities
         </strong>
         − In August 2020, the US Food and Drug Administration (FDA) announced detection of nitrosamine impurities in samples of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ]. Some such compounds have been implicated as possible carcinogens in long-term animal studies, with toxicity largely related to cumulative exposure. To preserve availability of rifampin and rifapentine for TB treatment, the FDA temporarily increased the maximum daily limits of these contaminants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We favor continued use of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         if acceptable to the patient, as the risk of not taking rifampin or rifapentine for TB treatment likely outweighs any potential risk from nitrosamine impurities; this approach is consistent with the United States Centers for Disease Control and Prevention (CDC) guidance issued in September 2020 [
         <a href="#rid17">
          17
         </a>
         ]. Precise levels of contamination for a given lot of drug are not provided to the consumer. However, the nitrosamine exposure is likely to be greater for the four-month rifapentine-moxifloxacin regimen than for the traditional regimen, given daily high dose, administration with a greater allowable limit for rifapentine [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Elevated levels of nitrosamine impurities have not been reported for
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2868865639">
         <span class="h4">
          Traditional regimen (≥6 months)
         </span>
         <span class="headingEndMark">
          —
         </span>
         This regimen including the drugs
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         (intensive phase of two months and continuation phase of at least four months); it remains standard of care.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimycobacterial agents
         </strong>
         − The traditional regimen (intensive phase of two months and continuation phase of at least four months) includes the drugs
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         (sometimes referred to as "RIPE therapy"; outside the United States, this regimen is known as 2HRZE/4HR)  (
         <a class="graphic graphic_table graphicRef50102" href="/z/d/graphic/50102.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef55978" href="/z/d/graphic/55978.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Traditional regimen (≥6 months)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing interval
         </strong>
         − Patients with TB and HIV infection should receive daily antituberculous therapy (five to seven days per week) during the intensive phase (initial two months of treatment) and during the continuation phase (at least four additional months after the intensive phase)  (
         <a class="graphic graphic_table graphicRef58653" href="/z/d/graphic/58653.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This approach is supported by a meta-analysis (largely comprised of cohort studies) in which thrice-weekly therapy in the initial phase was associated with higher rates of treatment failure than daily therapy (adjusted risk ratio 4.0, 95% CI 1.5-10.4) and relapse (adjusted risk ratio 4.8, 95% CI 1.8-12.8) [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequently, a randomized trial including 331 patients with HIV infection in India treated for TB with a daily, part-daily (daily treatment during the intensive phase and thrice-weekly treatment during the continuation phase), or fully intermittent (thrice weekly throughout treatment) regimen noted a favorable response (all sputum cultures negative during the last two months of treatment) in 91, 80, and 77 percent of cases, respectively [
         <a href="#rid22">
          22
         </a>
         ]. The trial was stopped prematurely based on the inferiority of the fully intermittent regimen and the observation of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         resistance in four of the patients in the fully intermittent treatment group (but in none of the patients in the other groups).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with TB and HIV infection (particularly those with &lt;100 CD4 lymphocytes/microL) should not be treated with regimens administered once or twice weekly [
         <a href="#rid6">
          6,23,24
         </a>
         ]. Among such patients, intermittent TB therapy has been identified as a risk factor for relapse and acquired rifamycin resistance [
         <a href="#rid23">
          23,25-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiretroviral therapy
         </strong>
         − Depending on the ART regimen chosen, adjustment of the antituberculous regimen may be required (for example,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         may need to be substituted for
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         in some cases). (See
         <a class="local">
          'Interactions between ART classes and the rifamycins'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Regimen selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1385914203">
         <span class="h4">
          Rifapentine-moxifloxacin-based (four-month) regimen
         </span>
         <span class="headingEndMark">
          —
         </span>
         This regimen may be used in patients &gt;12 years of age with drug-susceptible pulmonary TB and HIV infection with CD4 count ≥100 cell/microL [
         <a href="#rid2">
          2,30
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimycobacterial agents
         </strong>
         − The four-month regimen consists of an intensive phase (eight weeks of high-dose
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         administered once daily), followed by a continuation phase (nine weeks of rifapentine, isoniazid, and moxifloxacin also administered once daily)  (
         <a class="graphic graphic_table graphicRef131747" href="/z/d/graphic/131747.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiretroviral therapy
         </strong>
         − Use of ART for patients on the four-month regimen is restricted to efavirenz-based therapy (with
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         plus
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         , as used in the clinical trial).
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         may not be coadministered with any of the integrase inhibitors, protease inhibitors, or with
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4216125250">
         <span class="h5">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The four-month regimen should
         <strong>
          not
         </strong>
         be used for patients in the following categories [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with suspected or confirmed resistance to the medications in the regimen – Patients who have not received &gt;5 doses of antimycobacterial therapy in the preceding six months may be started on the four-month regimen while drug susceptibility testing is pending. Rapid drug susceptibility should be available; molecular testing for drug resistance (available from local or state public health laboratory) is advised.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with history of cardiac morbidities (given risk for fluoroquinolone-induced toxicity), including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of arrhythmias (especially bradyarrhythmias), uncorrected hypothyroidism or electrolyte imbalances
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of prolonged QTc or concurrent use of other QTc-prolonging medications  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of ischemic heart disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of sudden cardiac death
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with advanced liver disease, renal insufficiency, and/or laboratory abnormalities including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline transaminases &gt;3 times the upper limit of normal
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline total bilirubin &gt;2.5 times the upper limit of normal,
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline creatinine &gt;2 mg/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Baseline serum potassium &lt;3.5 mEq/L
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnant or lactating women
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients on drugs with potential for interactions with the medications in the regimen; specific interactions may be determined by using the
         <a class="external" href="/drug-interactions">
          drug interaction program
         </a>
         included within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with incomplete access to medication or inadequate reimbursement to complete a full course of treatment
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3000914667">
         <span class="h5">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to laboratory evaluation, electrocardiogram (EKG) monitoring, drug administration, chest radiography, and sputum monitoring is outlined below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baseline laboratory evaluation
         </strong>
         − Baseline laboratory evaluation should include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count (hemoglobin ≥7 g/dL, platelets ≥100,000/microL)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transaminases, alkaline phosphatase &lt;3 times the upper limit of normal
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Total bilirubin &lt;2.5 times the upper limit of normal
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Creatinine &lt;2 mg/dL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum potassium &gt;3.5 mEq/L
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum calcium and magnesium concentrations within normal limits
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnancy testing if indicated
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EKG monitoring
         </strong>
         –
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         is a QT-prolonging agent and has been associated with cardiac arrhythmias which may be fatal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We favor performing baseline EKG prior to starting treatment; we do not use a fluoroquinolone-based regimen for patients with baseline QTc &gt;450 ms (
         <a class="calc calc_professional" href="/z/d/html/13459.html" rel="external">
          calculator 1
         </a>
         ). For patients with normal baseline EKG, we perform subsequent EKG monitoring for QTc prolongation one to two weeks later, then at least monthly thereafter. We stop the regimen if QTc increases to ≥500 ms or increases by ≥60 ms over baseline [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'QT interval prolongation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview", section on 'QT prolongation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach differs from the CDC, which does not recommend EKG monitoring with the four-month regimen [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug dosing and administration
         </strong>
         − The rifapentine-moxifloxacin four-month regimen consists of an intensive phase (eight weeks of
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         administered once daily), followed by a continuation phase (nine weeks of rifapentine, isoniazid, and moxifloxacin administered once daily)  (
         <a class="graphic graphic_table graphicRef131747" href="/z/d/graphic/131747.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At least five of seven weekly doses should be administered under direct observation. (See
         <a class="medical medical_review" href="/z/d/html/8019.html" rel="external">
          "Adherence to tuberculosis treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Therapeutic drug level monitoring may be helpful if there is concern regarding malabsorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiography
         </strong>
         – Following initial evaluation, we obtain repeat chest radiograph at week 8 and at the completion of therapy [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sputum monitoring
         </strong>
         − Sputum should be obtained for acid-fast bacilli smear and culture at monthly intervals until two consecutive cultures are negative. A positive sputum culture at two months should prompt drug susceptibility testing of that isolate; patients with drug-resistant isolates should be evaluated for reasons for the emergence of drug resistance (eg, nonadherence, malabsorption).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3447178103">
         <span class="h5">
          Completing therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         − Patients typically demonstrate clinical improvement (with regard to cough, fever, weight loss) within two to three weeks of starting appropriate treatment.
        </p>
        <p>
         Completion of the regimen consists of 119 doses (56 intensive phase doses and 63 continuation phase doses). The intensive phase doses should be administered within 70 days from treatment initiation, and the continuation phase doses should be administered within 84 days from intensive phase completion.
        </p>
        <p>
         If these targets are not met, the patients should be considered to have interrupted therapy. Further management should be individualized in consultation with a TB expert, and might require switching to the traditional regimen [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1221948808">
         <span class="h5">
          Regimen efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of the four-month regimen is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">
          "Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Regimen efficacy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2025512053">
         <span class="h2">
          Antiretroviral therapy
         </span>
        </p>
        <p class="headingAnchor" id="H1059142102">
         <span class="h3">
          Timing
         </span>
        </p>
        <p class="headingAnchor" id="H131224098">
         <span class="h4">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with the World Health Organization (WHO), which recommends ART in all patients with HIV infection and TB disease, regardless of CD4 cell count [
         <a href="#rid4">
          4
         </a>
         ]. In addition, we agree with the United States Department of Health and Human Services (DHHS) and the American Thoracic Society (ATS)/CDC/Infectious Diseases Society of America (IDSA), which recommend "integrated ART" (eg, within two to eight weeks after initiating anti-TB therapy) rather than "sequential ART" (eg, after completion of antituberculous therapy) for all patients with HIV infection and TB disease [
         <a href="#rid1">
          1,6
         </a>
         ]. ART initiation should not be delayed until the completion of TB treatment; this approach has been associated with increased morbidity and mortality [
         <a href="#rid1">
          1,6
         </a>
         ]. (See
         <a class="local">
          'Evidence from clinical trials'
         </a>
         below.)
        </p>
        <p>
         TB medications and ART should not be initiated simultaneously. The optimal timing of integrated HIV and TB therapy depends on the patient's immune status [
         <a href="#rid1">
          1,3,4,6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with pulmonary TB and CD4 cell count &lt;50 cells/microL, ART should be initiated as soon as possible but within two weeks after initiation of TB treatment. This approach reduces the combined risk of an acquired immunodeficiency syndrome (AIDS)-defining illness and death, despite an increased risk for TB immune reconstitution inflammatory syndrome (IRIS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with pulmonary TB and CD4 count ≥50 cells/microL, ART should be initiated within eight weeks after initiation of TB treatment. In the absence of severe disease, early ART is not associated with a decreased risk of AIDS or death and later initiation of ART (eg, eight weeks) is associated with a lower risk of IRIS regardless of baseline CD4 cell count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with TB involving the central nervous system (CNS), ART should be delayed for the first eight weeks of antituberculous therapy, regardless of CD4 count. Issues related to CNS TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other clinical considerations (apart from immune status) may influence clinical decisions regarding the timing of ART. Later initiation of ART (eg, eight weeks) may be preferred based on the patient's tolerance of TB medications and ability to swallow multiple pills, while earlier initiation of ART (eg, within two weeks) may be considered in a patient with malnutrition or wasting, regardless of CD4 cell count.
        </p>
        <p>
         HIV drug-resistance testing should be performed in preparation for ART selection. The choice of ART depends on patient comorbidities, HIV drug-resistance patterns, and cost considerations. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3769.html" rel="external">
          "Overview of HIV drug resistance testing assays"
         </a>
         .)
        </p>
        <p>
         In patients with baseline CD4 cell counts &lt;100 cells/microL and starting ART within 30 days of starting antituberculous therapy, we favor prophylactic administration of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         during the first four weeks after initiation of ART; this intervention may reduce the likelihood of IRIS. (See
         <a class="local">
          'Preventing IRIS'
         </a>
         below.)
        </p>
        <p>
         Management of IRIS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         and
         <a class="local">
          'Preventing IRIS'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3523796940">
         <span class="h4">
          Evidence from clinical trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recommendation for integrated ART (initiation of ART during TB therapy) over sequential ART (initiating ART after completion of TB therapy) is based on data from a number of randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a systematic review and meta-analysis within the 2016 DHHS/ATS/IDSA guidelines including eight randomized trials and 4390 patients, initiation of ART during TB treatment was associated with 24 percent overall reduction in mortality (8 studies; risk ratio 0.76, 95% CI 0.57-1.01) [
         <a href="#rid1">
          1,34-41
         </a>
         ]. The overall risk of AIDS-defining illness or death was reduced by 34 percent with early or immediate ART (4 studies; risk ratio 0.66, 95% CI 0.47-0.91). Initiation of ART initiation during antituberculous therapy was associated with increased risk of IRIS (risk ratio 1.88, 95% CI 1.31-2.69). No increase in the risk of other adverse events was identified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the SAPIT trial (Starting Antiretroviral Therapy at Three Points in Tuberculosis), a randomized trial undertaken between 2005 and 2010, the incidence of grade 1 or higher increases in aspartate aminotransferase or alanine aminotransferase among patients who received TB treatment plus efavirenz-based ART in the early-integrated, late-integrated, and sequential ART treatment arms was 34, 30, and 29 percent [
         <a href="#rid42">
          42
         </a>
         ]. However, the rates of grade 3 or 4 liver toxicity were fairly low at 1, 4, and 2 percent, respectively.
        </p>
        <p>
        </p>
        <p>
         The recommendation for early versus delayed ART initiation is based on findings from a number of randomized trials. A systematic review and meta-analysis published in 2015 included eight randomized trials (more than 4500 adults with HIV infection and newly diagnosed pulmonary TB) that evaluated early versus delayed ART initiation (1 to 4 weeks versus 8 to 12 weeks after initiation of TB treatment) [
         <a href="#rid43">
          43
         </a>
         ]. Overall, lower mortality was observed with early ART compared with delayed ART (relative risk [RR] 0.81, 95% CI 0.66-0.99). Among patients with CD4 count &lt;50 cells/microL, lower mortality was observed with early ART compared with delayed ART (RR 0.71, 95% CI 0.54-0.93). Among patients with CD4 count ≥50 cells/microL, no mortality difference was observed between early and delayed ART (RR 1.05, 95% CI 0.68-1.61). Early ART was associated with a higher incidence of TB-IRIS than delayed ART regardless of CD4 count (for CD4 &lt;50 cells/microL: RR 2.50, 95% CI 1.84-3.40; for CD4 &gt;50 cells/microL: RR 2.21, 95% CI 1.50-3.24).
        </p>
        <p>
         Most studies on the timing of ART have been conducted in patients with smear-positive TB; this subset represents less than half of patients treated for pulmonary TB in resource-limited countries. For patients with smear-negative disease, it is not known if outcomes are comparable.
        </p>
        <p class="headingAnchor" id="H1725553942">
         <span class="h3">
          Preventing IRIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical worsening of a pre-existing infectious process (eg, TB) following immune recovery associated with administration of ART [
         <a href="#rid44">
          44-49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'
         </a>
         .)
        </p>
        <p>
         In patients with low baseline CD4 cell counts &lt;100 cells/microL and starting ART within 30 days of starting antituberculous therapy, we favor prophylactic administration of low-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 mg daily for two weeks, followed by 20 mg daily for two weeks) during the first four weeks after initiation of ART; this intervention may reduce the likelihood of IRIS.
        </p>
        <p>
         This strategy is supported by a randomized trial including more than 200 adults with HIV infection (CD4 count ≤100 cells/microL) who were initiating ART and had started antituberculous therapy within 30 days before initiating ART; the incidence of TB-associated IRIS was lower among those who received
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 mg per day for 14 days, then 20 mg per day for 14 days) than those who received placebo (32 versus 47 percent; RR 0.7, 95% CI 0.51-0.96) [
         <a href="#rid50">
          50
         </a>
         ]. There was no increased risk of severe infection or cancer; the trial was underpowered to detect a difference in mortality.
        </p>
        <p class="headingAnchor" id="H2747141999">
         <span class="h3">
          Regimen selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The selection of the ART regimen depends on multiple factors including virologic potency, convenience, patient comorbidities, drug resistance, drug interactions with antituberculous therapy, and cost. When feasible, it is preferable to select an ART regimen that is compatible with a rifamycin-based antituberculous regimen. (See
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         below.)
        </p>
        <p>
         The selection of ART regimens and the issues related to the various antiretroviral drug classes for the treatment of HIV are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1348515847">
         <span class="h1">
          HIV DIAGNOSED PRIOR TO TB
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HIV infection who are already on antiretroviral therapy (ART) should continue ART and initiate antituberculous therapy with a rifamycin as soon as possible.
        </p>
        <p class="headingAnchor" id="H4105042125">
         <span class="h2">
          Antiretroviral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If viral suppression has been attained and the current ART regimen is well tolerated, the ART regimen should be continued if possible and the antituberculous regimen adjusted accordingly.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Antituberculous therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3230097013">
         <span class="h3">
          Regimen selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to selection of antituberculous therapy in adults with HIV infection is discussed above. (See
         <a class="local">
          'Regimen selection'
         </a>
         above.)
        </p>
        <p>
         A rifamycin is a key component of TB treatment [
         <a href="#rid6">
          6
         </a>
         ].
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         are considered comparable in terms of activity against
         <em>
          Mycobacterium tuberculosis
         </em>
         . For patients with HIV infection treated with the traditional regimen, the choice of rifamycin is governed by HIV drug interactions, availability, and cost considerations. For patients treated with the rifapentine-moxifloxacin-based (four-month) regimen, rifabutin may not be substituted for rifapentine. (See
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         below.).
        </p>
        <p>
         There are a number of interactions between rifamycins and antiretroviral agents. The main consideration in choice of antituberculous therapy consists of selecting a rifamycin that will minimize the likelihood of significant drug interactions with ART and interference with HIV viral suppression (see
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose ART regimen contains
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF),
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         may be used with caution, but the combination has not been tested to confirm virologic efficacy [
         <a href="#rid51">
          51
         </a>
         ]. Use of TAF with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         is not recommended; substitution of
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         (TDF) should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose ART regimen contains a protease inhibitor,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         is the preferred rifamycin.
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         should not be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose ART regimen contains a non-nucleoside reverse-transcriptase inhibitor (NNRTI), the rifamycin used depends on the NNRTI:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients receiving
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         is the preferred rifamycin;
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         could also be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients receiving
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         , or
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         should be administered with dose adjustments, as necessary.
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         should not be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients receiving
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         is the preferred rifamycin; however, interaction between these drugs may increase rifabutin exposure and, with this, risk for rifabutin toxicity. We use
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         with nevirapine in select situations for patients who are virologically suppressed [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         has fewer drug interactions than
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ; however, rifampin is more cost effective than rifabutin in resource-limited settings. (See
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients whose ART regimen contains an integrase strand transfer inhibitor (INSTI): the dose of some INSTIs (
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ) should be doubled if
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         is given.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          Dolutegravir
         </a>
         and
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         may be administered with either
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ; the dose of these drugs should be doubled (ie, given twice daily) if given with rifampin (for example, dolutegravir dosing would be 50 mg orally twice daily rather than 50 mg orally once daily).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          Cabotegravir
         </a>
         may be administered with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         but not with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other INSTIs (bictegravir, elvitegravir-cobicistat) should
         <strong>
          not
         </strong>
         be coadministered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DRUG INTERACTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1128744305">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Careful review for drug interactions is essential when considering antituberculous therapy in patients taking antiretroviral therapy (ART). Such interactions can interfere with efficacy of therapy for either HIV or TB infection. A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         .
        </p>
        <p class="headingAnchor" id="H401496881">
         <span class="h2">
          TB regimens based on the rifamycin component
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rifamycins induce hepatic CYP3A4 enzymes that can accelerate metabolism of protease inhibitors (PIs) and some non-nucleoside reverse transcriptase inhibitors (NNRTIs) [
         <a href="#rid6">
          6,52
         </a>
         ].
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         is a much more potent inducer than
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         . Conversely, serum concentrations of rifabutin may be decreased by the concomitant administration of certain antiretroviral drugs (eg,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ).
        </p>
        <p>
         Despite the complexity of managing drug interactions, rifamycins are integral to the success of TB therapy and should not be substituted with other antituberculous medications based on concerns regarding drug interactions alone [
         <a href="#rid6">
          6,52
         </a>
         ]. The following sections address selection of antiretroviral medications with either a rifampin- or a rifabutin-based TB regimen.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rifapentine-based regimen
         </strong>
         − Use of ART for patients on the rifapentine-moxifloxacin-based (four-month) regimen is restricted to efavirenz-based therapy (with
         <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">
          tenofovir disoproxil fumarate
         </a>
         [TDF] plus
         <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">
          lamivudine
         </a>
         or
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         , as used in the clinical trial) [
         <a href="#rid30">
          30
         </a>
         ].
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         may not be coadministered with any of the integrase inhibitors, PIs, or with
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         (TAF). (See
         <a class="local">
          'Regimen selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rifampin-based regimens
         </strong>
         − A limited number of antiretroviral medications within a limited number of drug classes can be coadministered with rifampin-based TB treatment, due to drug interactions that adversely affect HIV treatment efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The ART regimen most commonly administered concomitantly with a rifampin-based TB regimen consists of the NNRTI
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         , together with two nucleoside analogs [
         <a href="#rid6">
          6,53
         </a>
         ]. Regimens that include the integrase strand transfer inhibitors (INSTIs)
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         or
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         (but not bictegravir,
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          cabotegravir
         </a>
         , or elvitegravir-cobicistat), may also be administered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         at double the dose [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug interaction information related to specific ART drug classes and rifampin-based TB therapy is discussed below. (See
         <a class="local">
          'Interactions between ART classes and the rifamycins'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rifabutin-based regimens
         </strong>
         −
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         is associated with fewer drug-drug interactions with antiretroviral agents than
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         . Rifabutin is as effective as rifampin for treatment of TB when used in combination therapy. However, rifabutin is more expensive than rifampin and distribution is limited in resource-limited settings. The adverse effects of rifampin and rifabutin are comparable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         may be coadministered with nucleoside analogs (except TAF), PIs, NNRTIs, and INSTIs (except elvitegravir-cobicistat and bictegravir). The standard dose of rifabutin is 300 mg daily; however, when dosed with ART, rifabutin often requires dose adjustments depending on the coadministered drug. A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         is a substrate for CYP3A4. Thus, its serum concentration is affected by the degree to which CYP3A4 is inhibited or induced by the coadministered drug  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Drug interaction information related to specific ART drug classes and rifabutin-based TB therapy is discussed below. (See
         <a class="local">
          'Interactions between ART classes and the rifamycins'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1406331775">
         <span class="h2">
          Interactions between ART classes and the rifamycins
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nucleoside analogs
         </strong>
         –
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         may be coadministered with TDF. Rifapentine should not be coadministered with TAF given possibility of decreased TAF concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-nucleoside reverse transcriptase inhibitors
         </strong>
         –
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         may be coadministered with
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         . Rifapentine should not be coadministered with
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         due to significantly decreased concentrations.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Protease inhibitors
         </strong>
         –
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         should not be administered with any protease inhibitor due to significantly decreased concentrations. Rifapentine also should not be given with
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         , a pharmacokinetic booster/CYP3A inhibitor often used with protease inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Integrase inhibitors
         </strong>
         –
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          Rifapentine
         </a>
         given daily should not be administered with bictegravir,
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          cabotegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         , or
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nucleoside analogs
         </strong>
         − Nucleoside analogs may be coadministered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ; a notable exception is TAF. Rifampin decreases drug levels of TAF, so TAF should generally not be given with rifamycins [
         <a href="#rid6">
          6
         </a>
         ]. Rifamycins are potent inducers of P-glycoprotein and TAF is a P-glycoprotein substrate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The nucleotide analog TDF does not have substantial interactions with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , so TDF and rifampin may be coadministered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-nucleoside reverse transcriptase inhibitors
         </strong>
         − For patients receiving NNRTI-based ART with a rifampin-based TB regimen, the preferred NNRTI is
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         . Viral suppression rates are more favorable with efavirenz-based than nevirapine-based ART; this is because use of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         reduces
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         concentrations to a greater degree than efavirenz concentrations [
         <a href="#rid6">
          6,53-57
         </a>
         ]. In addition, several trials of ART in treatment-naïve patients have shown that nevirapine is associated with higher rates of hepatotoxicity than efavirenz [
         <a href="#rid58">
          58
         </a>
         ]; this is important since antituberculous agents can also cause drug-induced liver injury. (See
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The appropriate dose of
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         is somewhat controversial [
         <a href="#rid6">
          6,53
         </a>
         ]. We are in agreement with the United States Department of Health and Human Services and United States Centers for Disease Control and Prevention guidelines, which favor the standard efavirenz dose (600 mg daily) among individuals treated with rifampin [
         <a href="#rid6">
          6
         </a>
         ]. Efavirenz levels are generally higher in patients from Southern Africa, West Africa, and India due to varying pharmacogenetics of efavirenz among different ethnic and racial groups [
         <a href="#rid59">
          59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Initiation of
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         should be avoided in patients who are already on antituberculous therapy, due to risk of virologic failure. However, patients on nevirapine-containing ART who have achieved virologic suppression and develop TB may continue the same ART regimen [
         <a href="#rid53">
          53
         </a>
         ]. This was illustrated in a cohort study including more than 2000 patients in South Africa; virologic outcomes were comparable among patients starting efavirenz-based ART with and without concurrent TB and in patients in whom TB developed while taking established nevirapine- or efavirenz-based therapies [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         is administered to patients on
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , nevirapine dosing consists of 200 mg twice daily (with no lead-in phase) [
         <a href="#rid6">
          6
         </a>
         ]. Increasing the dose of nevirapine further is not beneficial. In one trial comparing standard dosing of nevirapine (200 mg twice daily) with a higher dose (300 mg twice daily), increased rates of hypersensitivity were observed among those randomized to the higher dose [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The NNRTIs
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         , and
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         should not be used with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ]. Rifampin substantially decreases concentrations of all three drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Protease inhibitors
         </strong>
         − PI-based ART should not be administered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ].
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         , rather than rifampin, should be used when PIs are used for HIV therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In patients with HIV infection initiating ART, PIs are usually dosed with the pharmacokinetic enhancer
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         , which boosts serum drug levels. Administration of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         with boosted PIs is associated with reduction of PI levels by as much as 95 percent [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Some studies have evaluated dose increments of a particular PI (eg, lopinavir or
         <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">
          atazanavir
         </a>
         ) to determine if serum concentrations can be maintained with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         . However, this approach has been associated with significant adverse events including gastrointestinal intolerance and hepatotoxicity and is not recommended [
         <a href="#rid63">
          63-66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Integrase inhibitors
         </strong>
         −
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         may be coadministered with caution; viral load monitoring is required. We favor doubling the dose of raltegravir when coadministered with rifampin [
         <a href="#rid67">
          67
         </a>
         ]. Rifampin decreases serum levels of raltegravir by 40 to 61 percent [
         <a href="#rid68">
          68
         </a>
         ]. Standard raltegravir dosing (400 mg twice daily) may be sufficient [
         <a href="#rid69">
          69,70
         </a>
         ]; doubling the dose of raltegravir (to 800 mg twice daily) improves drug levels [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         may be coadministered; in such circumstances, we favor doubling the dose of dolutegravir (from 50 mg once daily to 50 mg twice daily) [
         <a href="#rid6">
          6,71,72
         </a>
         ], given a significant drug-drug interaction between dolutegravir and rifampin resulting in a 56 percent reduction in the area under the curve (AUC) of dolutegravir [
         <a href="#rid73">
          73
         </a>
         ]. This approach is supported by a randomized trial including more than 100 patients with TB (on rifampin-based treatment for ≤8 weeks) and HIV (ART naïve) randomly assigned to initiation of ART with two nucleoside reverse transcriptase inhibitors and either dolutegravir (twice-daily dosing) or
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         [
         <a href="#rid71">
          71
         </a>
         ]. Double-dose dolutegravir was well tolerated; the trial was not powered to compare virologic efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         should not be administered with the fixed-dose combination of
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         , tenofovir, and
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         , as rifampin is expected to decrease concentrations of both elvitegravir and cobicistat [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Bictegravir should not be administered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         because bictegravir levels are significantly decreased by rifampin [
         <a href="#rid74">
          74
         </a>
         ]. Doubling the dose of bictegravir does not adequately overcome the inducing effect of rifampin; in one study, plasma bictegravir AUC was 60 percent lower when coadministered with rifampin, even when double the recommended dose was given [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          Cabotegravir
         </a>
         should not be administered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         because rifampin is expected to decrease cabotegravir concentrations significantly.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other ART classes
         </strong>
         −
         <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">
          Maraviroc
         </a>
         (a CCR5 receptor antagonist) should not be coadministered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ]. Rifampin decreases serum levels of maraviroc by 78 percent; there is no published experience regarding efficacy or toxicity of this combination.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="128916" href="/z/d/drug information/128916.html" rel="external">
          Fostemsavir
         </a>
         (CD4 attachment inhibitor) should not be coadministered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , as rifampin significantly decreases fostemsavir concentrations [
         <a href="#rid75">
          75,76
         </a>
         ]; however,
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         has only a weak interaction and can be coadministered [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="8609" href="/z/d/drug information/8609.html" rel="external">
          Enfuvirtide
         </a>
         (a fusion inhibitor) or
         <a class="drug drug_general" data-topicid="117178" href="/z/d/drug information/117178.html" rel="external">
          ibalizumab
         </a>
         (CD4 postattachment inhibitor) may be coadministered with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ; there are no interactions between these drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nucleoside analogs
         </strong>
         − Nucleoside analogs may be coadministered with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ; a notable exception is TAF. Rifabutin decreases drug levels of TAF, so TAF should not be given [
         <a href="#rid6">
          6
         </a>
         ]. Rifamycins are potent inducers of P-glycoprotein and TAF is a P-glycoprotein substrate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The nucleotide analog TDF does not have substantial interactions with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         , so TDF and rifabutin may be coadministered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-nucleoside reverse transcriptase inhibitors
         </strong>
         −
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          Efavirenz
         </a>
         can reduce serum concentrations of
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         . Therefore, if efavirenz is administered, the dose of rifabutin should be increased from the standard dose of 300 mg to 450 to 600 mg/day [
         <a href="#rid6">
          6,78
         </a>
         ]. A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are no significant drug interactions between
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         and
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         can be given with
         <a class="drug drug_general" data-topicid="118920" href="/z/d/drug information/118920.html" rel="external">
          doravirine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8902" href="/z/d/drug information/8902.html" rel="external">
          etravirine
         </a>
         , or
         <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">
          rilpivirine
         </a>
         ; dose adjustments may be necessary [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Protease inhibitors
         </strong>
         − PIs can be coadministered with
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         without significantly compromising the serum drug concentrations, with or without the coadministration of
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         or
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         for pharmacologic boosting [
         <a href="#rid79">
          79
         </a>
         ]. The dose of rifabutin should be decreased from 300 mg daily to 150 mg daily (or 300 mg three times per week). A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         dose previously recommended for coadministration with ritonavir-boosted PIs (150 mg three times weekly) has been associated with insufficient rifabutin levels [
         <a href="#rid80">
          80
         </a>
         ]. In addition, there have been reports of acquired rifamycin resistance among individuals receiving this dose [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are no published data on coadministration of
         <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">
          darunavir
         </a>
         and
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Integrase inhibitors
         </strong>
         −
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         does not appear to substantially affect
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         , or
         <a class="drug drug_general" data-topicid="130319" href="/z/d/drug information/130319.html" rel="external">
          cabotegravir
         </a>
         concentrations (based on limited in vitro data) [
         <a href="#rid72">
          72,82
         </a>
         ]. If coadministered with rifabutin, the doses of raltegravir, dolutegravir, or cabotegravir do not need to be increased [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         should not be used with the fixed-dose combination of
         <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">
          elvitegravir
         </a>
         ,
         <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">
          cobicistat
         </a>
         , tenofovir, and
         <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">
          emtricitabine
         </a>
         , given decreased elvitegravir levels. Likewise, rifabutin should not be used with bictegravir; in one study, rifabutin coadministration resulted in a 38 percent reduction in AUC [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other ART classes
         </strong>
         − There are no published data on the combined use of
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         and
         <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">
          maraviroc
         </a>
         . Dosing recommendations vary according to the concomitant medications [
         <a href="#rid6">
          6
         </a>
         ]. A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are no drug interactions between
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         and either the fusion inhibitor
         <a class="drug drug_general" data-topicid="8609" href="/z/d/drug information/8609.html" rel="external">
          enfuvirtide
         </a>
         , the CD4 attachment inhibitor
         <a class="drug drug_general" data-topicid="128916" href="/z/d/drug information/128916.html" rel="external">
          fostemsavir
         </a>
         , or the CD4 postattachment inhibitor
         <a class="drug drug_general" data-topicid="117178" href="/z/d/drug information/117178.html" rel="external">
          ibalizumab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H508871804">
         <span class="h1">
          TREATMENT FAILURE OR RELAPSE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment failure
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For the traditional regimen, treatment failure refers to positive sputum cultures after four months of antituberculous therapy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For the rifapentine-moxifloxacin four-month regimen, lack of clinical, radiographic, or microbiologic improvement at eight weeks of treatment should prompt complete re-evaluation of the patient and treatment regimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Relapse
         </strong>
         − Relapse refers to recurrent TB at any time after completion of treatment with apparent cure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Most relapses occur within the first 6 to 12 months following completion of therapy. Among patients with drug-susceptible TB, relapse occurs in approximately 5 percent of cases [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Relapse may occur as a result of relapsed infection due to the same
         <em>
          M. tuberculosis
         </em>
         strain (more common in low-incidence settings) or due to exogenous reinfection with a new strain (more common in high-incidence settings) [
         <a href="#rid85">
          85-89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Among patients treated with rifamycin-containing regimens using directly observed therapy (DOT), relapse generally occurs with susceptible organisms. If initial drug susceptibility testing was not performed and the patient fails or relapses with a rifamycin-containing regimen given by DOT, there is high likelihood that the organism was resistant from the outset.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         − Risk factors for treatment failure and relapse include [
         <a href="#rid90">
          90-93
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High burden of disease (presence of cavitary disease, bilateral disease, and/or extrapulmonary disease)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug resistance
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inadequate treatment adherence
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malabsorption (if malabsorption is suspected, drug level testing may be useful)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malnourishment
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug susceptibility testing
         </strong>
         − If treatment failure or relapse is confirmed or suspected, the
         <em>
          M. tuberculosis
         </em>
         isolate should be sent for drug susceptibility testing to first- and second-line agents. In clinical and public health laboratories, drug resistance is evaluated by assessing growth of in the presence of a "critical concentration" of drug (defined as the lowest concentration of drug that inhibit 95 percent of "wild-type strains") [
         <a href="#rid94">
          94
         </a>
         ]. In the United States, specimens may be forwarded to the Centers for Disease Control and Prevention for molecular testing with relatively rapid turnaround time [
         <a href="#rid95">
          95,96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'Microbiologic testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         − The approach to management of treatment failure and relapse is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8028.html" rel="external">
          "Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Empiric treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1234662340">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111822.html" rel="external">
          "Society guideline links: Diagnosis and treatment of tuberculosis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">
          "Society guideline links: Opportunistic infections in adults with HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical approach to treatment of tuberculosis (TB) in patients with HIV infection depends upon which condition is diagnosed first. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with an established diagnosis of TB disease require prompt initiation of antituberculous therapy. Empiric treatment of TB infection may be appropriate in patients for whom there is high clinical suspicion for TB (based on epidemiologic exposure, physical findings, radiographic findings, and supportive laboratory data) but no definitive laboratory diagnosis. In contrast, we suggest
         <strong>
          against
         </strong>
         routine administration of empiric antituberculous therapy in patients with HIV infection (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In one trial, empiric treatment in these patients was associated with similar mortality rate but increased adverse events compared to test-guided treatment. (See
         <a class="local">
          'Role of empiric TB therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with HIV and TB, an empiric four-drug regimen should be initiated (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ) with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         and daily therapy using clinical case management and directly observed therapy (DOT) until drug susceptibility results are available  (
         <a class="graphic graphic_table graphicRef58653" href="/z/d/graphic/58653.html" rel="external">
          table 1
         </a>
         ). Depending on the antiretroviral therapy (ART) regimen chosen, adjustment of the antituberculous regimen may be required. (See
         <a class="local">
          'TB diagnosed prior to HIV'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For treatment of drug-susceptible TB in patients with HIV infection, we suggest treatment with the traditional (≥6 month) regimen (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The shortened rifapentine-moxifloxacin-based (four-month) regimen is a potential alternative regimen for patients &gt;12 years and CD4 &gt;100 cells/microL. Use of the shortened regimen requires attention to ART drug interactions (
         <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">
          rifapentine
         </a>
         may not be coadministered with integrase inhibitors or
         <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">
          tenofovir alafenamide
         </a>
         [TAF]) as well as more detailed programmatic considerations. (See
         <a class="local">
          'Regimen selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with HIV infection and pulmonary TB who are not already on ART, we recommend initiation of ART during TB treatment (eg, within two to eight weeks after initiating antituberculous therapy) rather than waiting until after completion of TB treatment (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (see
         <a class="local">
          'Timing'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with CD4 cell count &lt;50 cells/microL, we recommend starting ART within two weeks after starting antituberculous therapy (rather than at later time points) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Studies suggest that this approach is associated with a lower risk of mortality, although higher rates of immune reconstitution inflammatory syndrome (IRIS).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with CD4 count ≥50, we suggest deferring initiation of ART to eight weeks after starting antituberculous therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Studies suggest that in this group, delayed versus early treatment has an uncertain impact on mortality and a lower rate of IRIS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with HIV infection and TB involving the central nervous system (CNS), ART should be delayed for the first eight weeks of antituberculous therapy, regardless of CD4 count. Issues related to CNS TB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">
          "Central nervous system tuberculosis: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with HIV infection and baseline CD4 cell count &lt;100 cells/microL on antituberculous therapy and initiating ART within 30 days of starting antituberculous therapy, we suggest prophylactic administration of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         during the first four weeks following initiation of ART (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ); this intervention may reduce the likelihood of IRIS. (See
         <a class="local">
          'Preventing IRIS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with HIV infection who are already on ART should continue the ART regimen and initiate antituberculous therapy with a rifamycin as soon as possible. If viral suppression has been attained and the current ART regimen is well tolerated, the ART regimen should be continued and the antituberculous or antiretroviral regimen adjusted accordingly with consideration for drug-drug interactions. (See
         <a class="local">
          'HIV diagnosed prior to TB'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pending drug susceptibility results, an empiric four-drug regimen should be initiated (
         <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">
          isoniazid
         </a>
         , a rifamycin [eg,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         or
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          rifabutin
         </a>
         ],
         <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">
          pyrazinamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         ) with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         and daily therapy using DOT  (
         <a class="graphic graphic_table graphicRef58653" href="/z/d/graphic/58653.html" rel="external">
          table 1
         </a>
         ). The main consideration consists of selecting a rifamycin that will minimize the likelihood of drug interactions with ART and interference with HIV viral suppression. A useful tool for HIV drug interactions may be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hiv-druginteractions.org%2F&amp;token=z%2Bmt1N5aL9bgwch2eXBa3nVeg3OY44JHdupzx%2B4Z6XlpU29xyvQyvDIICJk1mV2C&amp;TOPIC_ID=8013" target="_blank">
          online
         </a>
         . (See
         <a class="local">
          'Antituberculous therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When feasible, it is preferable to select an ART regimen that is compatible with a rifamycin-based antituberculous regimen. However, there are a number of drug interactions between
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and antiretroviral agents.
         <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">
          Rifabutin
         </a>
         is as effective as rifampin for treatment of TB when used in combination therapy and is associated with fewer drug interactions with antiretroviral agents than rifampin. However, rifabutin is more expensive than rifampin, and distribution is limited in resource-limited settings. The adverse effects of rifampin and rifabutin are comparable. (See
         <a class="local">
          'Regimen selection'
         </a>
         above and
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with TB and HIV who are receiving a rifampin-based antituberculous regimen, we suggest an ART regimen consisting of the integrase inhibitors
         <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">
          raltegravir
         </a>
         or
         <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">
          dolutegravir
         </a>
         (at double dose), or the non-nucleoside reverse transcriptase inhibitor (NNRTI)
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         , together with two nucleoside analogs (except TAF) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with TB and HIV who are receiving a rifabutin-based antituberculous regimen, we suggest either a protease inhibitor, NNRTI, or compatible integrase inhibitor, together with two nucleoside analogs (except TAF) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'TB regimens based on the rifamycin component'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Issues related to follow-up and duration of therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8030.html" rel="external">
          "Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.
          </a>
         </li>
         <li class="breakAll">
          Clinicalinfo.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines (Accessed on January 16, 2024).
         </li>
         <li class="breakAll">
          World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1 (Accessed on January 16, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onyebujoh PC, Ribeiro I, Whalen CC. Treatment Options for HIV-Associated Tuberculosis. J Infect Dis 2007; 196 Suppl 1:S35.
          </a>
         </li>
         <li class="breakAll">
          Clinicalinfo.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on January 16, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntshanga SP, Rustomjee R, Mabaso ML. Evaluation of directly observed therapy for tuberculosis in KwaZulu-Natal, South Africa. Trans R Soc Trop Med Hyg 2009; 103:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anuwatnonthakate A, Limsomboon P, Nateniyom S, et al. Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One 2008; 3:e3089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014; 65:e8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gesesew HA, Ward P, Woldemichael K, Mwanri L. Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors. BMC Infect Dis 2018; 18:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanc FX, Badje AD, Bonnet M, et al. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. N Engl J Med 2020; 382:2397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016; 387:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant AD, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. Lancet HIV 2020; 7:e27.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine (Accessed on October 06, 2020).
         </li>
         <li class="breakAll">
          United States Centers for Disease Control and Prevention. Dear Colleague Letters: Update on Rifamycin Issues. https://www.cdc.gov/tb/publications/letters/Rifamycin_Update.html (Accessed on October 19, 2020).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Laboratory analysis of rifampin/rifapentine products. https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-rifampinrifapentine-products (Accessed on April 05, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial. JAMA Intern Med 2018; 178:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narendran G, Menon PA, Venkatesan P, et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis 2014; 59:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettit AC, Phillips PPJ, Kurbatova E, et al. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis 2023; 76:e580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes G, Bern H, Chiang CY, et al. QT prolongation in the STREAM Stage 1 Trial. Int J Tuberc Lung Dis 2022; 26:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motta I, Cozzi SN, Pontali E. QT prolongation for old and new drugs: how much should we really worry? Int J Tuberc Lung Dis 2022; 26:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014; 14:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012; 60:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shao HJ, Crump JA, Ramadhani HO, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses 2009; 25:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha S, Shekhar RC, Singh G, et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis 2012; 12:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidoo K, Hassan-Moosa R, Mlotshwa P, et al. High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial. Clin Infect Dis 2020; 70:2675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med 2018; 379:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerrone M, Alfarisi O, Neary M, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 2019; 74:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonnet M, Bhatt N, Baudin E, et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis 2013; 13:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stöhr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross R, Aplenc R, Tenhave T, et al. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 2008; 49:336.
          </a>
         </li>
         <li class="breakAll">
          Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 12 weeks efficacy of nevirapine, 400 mg vs. 600 mg per day in HIV-infected patients with active TB receiving rifampicin: a multicenter study. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acosta EP, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51:3104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           L'homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011; 66:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014; 14:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taburet AM, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clin Infect Dis 2015; 61:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis 2020; 70:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013; 62:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents 2019; 54:202.
          </a>
         </li>
         <li class="breakAll">
          Custodio JM, West SK, Collins S et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. 25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston, MA.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahine EB. Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection. Am J Health Syst Pharm 2021; 78:376.
          </a>
         </li>
         <li class="breakAll">
          Hruska M, Anderson J, Bedford B, et al. The effect of rifampin on the pharmacokinetics of the HIV-1 attachment inhibitor prodrug BMS-663068 in healthy subjects. 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2013, abstract P_05.
         </li>
         <li class="breakAll">
          Adamcyzk R, Griffies A, Ravindran P, et al. HIV-1 attachment inhibitor prodrug BMS-663068: interactions with rifabutin, with or without ritonavir, in healthy subjects. 8th International AIDS Society Conference, Vancouver, July 2015, abstract TUPEB277.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner M, Benator D, Peloquin CA, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 2005; 41:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           TB/HIV drug interactions. MMWR Morb Mortal Wkly Rep 2004; 53:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010; 54:4440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol 2011; 51:943.
          </a>
         </li>
         <li class="breakAll">
          Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. http://www.croiconference.org/sessions/clinical-pharmacology-hiv-integrase-strand-transfer-inhibitor-bictegravir (Accessed on August 20, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert ML, Hasker E, Van Deun A, et al. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 2014; 58:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jasmer RM, Bozeman L, Schwartzman K, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang KC, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korenromp EL, Scano F, Williams BG, et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37:101.
          </a>
         </li>
         <li class="breakAll">
          Association of Public Health Laboratories. TB Drug-Susceptibility Testing Expert Panel Meeting. Summary Report. December 12-13, 2007. https://www.aphl.org/programs/infectious_disease/tuberculosis/Documents/ID_2007Dec_TB-DST-Report.pdf (Accessed on January 31, 2020).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Tuberculosis: Laboratory Information. http://www.cdc.gov/tb/topic/laboratory/ (Accessed on June 16, 2016).
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Reference Laboratory Division of TB Elimination Laboratory User Guide
for U.S. Public Health Laboratories: Molecular Detection of Drug Resistance (MDDR) in Mycobacterium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. CDC, Atlanta, GA 2012. http://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdf (Accessed on June 16, 2016).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8013 Version 89.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17726832" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment Options for HIV-Associated Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17726832" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment Options for HIV-Associated Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8139628" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15941807" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19394664" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of directly observed therapy for tuberculosis in KwaZulu-Natal, South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18769479" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Directly observed therapy and improved tuberculosis treatment outcomes in Thailand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24419071" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29378523" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Late presentation for HIV care in Southwest Ethiopia in 2003-2015: prevalence, trend, outcomes and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32558469" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27025337" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31727580" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31727580" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31727580" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31727580" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19542476" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20353364" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22820541" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29507938" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11922192" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19368504" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359410" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965813" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14986259" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25156114" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16109981" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36041016" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35351238" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : QT prolongation in the STREAM Stage 1 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35351233" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : QT prolongation for old and new drugs: how much should we really worry?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22010915" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Integration of antiretroviral therapy with tuberculosis treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22010913" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22010914" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24810491" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20181971" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Timing of initiation of antiretroviral drugs during tuberculosis therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22592586" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20001518" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22846195" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31622456" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26148280" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9655723" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10628452" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18652998" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22944873" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578375" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255740" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30428290" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30815689" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005814" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18677025" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032533" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19438397" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23433590" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890776" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786975" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18771051" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19704172" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&gt;T polymorphism on efavirenz concentrations in adults in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978480" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Slow efavirenz metabolism genotype is common in Botswana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18978480" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Slow efavirenz metabolism genotype is common in Botswana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17576825" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17352770" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19194314" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19352137" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19433563" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131695" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Emerging antiretroviral drug interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24726095" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26105170" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30918967" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23075918" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002950" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002950" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33547469" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33547469" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33547469" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16206114" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : TB/HIV drug interactions
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19807276" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660678" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20852006" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20852006" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12726976" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Recurrence in tuberculosis: relapse or reinfection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2155569" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15831840" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24647020" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11728545" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15477492" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Recurrent tuberculosis in the United States and Canada: relapse or reinfection?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12241657" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10513648" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15374844" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830415" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
